{"id":"comparator-placebo-to-pioglitazone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5","effect":"Headache"},{"rate":"5","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pioglitazone binds to PPAR-γ, a nuclear receptor expressed primarily in adipose tissue, muscle, and liver. This activation increases insulin sensitivity by enhancing glucose uptake and reducing hepatic glucose production, thereby lowering blood glucose in patients with type 2 diabetes. The drug also has anti-inflammatory effects and may improve lipid profiles.","oneSentence":"Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:17.247Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT00500331","phase":"PHASE2","title":"Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-23","conditions":"Diabetes Mellitus, Type 2","enrollment":334},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00511108","phase":"PHASE1","title":"Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":211},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT00745914","phase":"NA","title":"Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2008-09","conditions":"Endstage Renal Disease, Diabetes","enrollment":22},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT01280123","phase":"PHASE2","title":"Pioglitazone in Early Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":210},{"nctId":"NCT01115712","phase":"PHASE1","title":"Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Healthy, Overweight, Obesity","enrollment":35},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00543959","phase":"PHASE2","title":"Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06","conditions":"Diabetes Mellitus Type 2","enrollment":346},{"nctId":"NCT00353587","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-05","conditions":"Type 2 Diabetes","enrollment":396},{"nctId":"NCT01103414","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Metabolic Solutions Development Company","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":356},{"nctId":"NCT00814372","phase":"PHASE2","title":"Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus","enrollment":242},{"nctId":"NCT02265276","phase":"PHASE3","title":"A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease","status":"UNKNOWN","sponsor":"Command Hospital, India","startDate":"2014-10","conditions":"Fatty Liver","enrollment":100},{"nctId":"NCT01322308","phase":"PHASE4","title":"Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Heart Institute, Mexico","startDate":"2007-03","conditions":"Systemic Lupus Erythematosus","enrollment":30},{"nctId":"NCT01280695","phase":"PHASE2","title":"A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Metabolic Solutions Development Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":129},{"nctId":"NCT01230749","phase":"PHASE2","title":"A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT00760578","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator","status":"COMPLETED","sponsor":"Metabolic Solutions Development Company","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus","enrollment":86},{"nctId":"NCT01109030","phase":"PHASE2, PHASE3","title":"Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2010-04","conditions":"Major Depressive Disorder","enrollment":50},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT00521742","phase":"PHASE3","title":"Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-03","conditions":"Diabetes Mellitus","enrollment":300},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00521820","phase":"PHASE3","title":"Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure","status":"TERMINATED","sponsor":"Takeda","startDate":"2000-06","conditions":"Diabetes Mellitus","enrollment":518},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367},{"nctId":"NCT00515632","phase":"PHASE3","title":"Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy","status":"COMPLETED","sponsor":"Rheoscience A/S","startDate":"2007-07","conditions":"Diabetes Mellitus, Type 2","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":408,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: placebo to pioglitazone","genericName":"Comparator: placebo to pioglitazone","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}